Asthma Pipeline Insight | Companies – Jiangsu Hengrui Medicine, GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., and Others
DelveInsight’s, “Asthma Pipeline Insight 2023” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in the Asthma pipeline landscape. It covers the Asthma pipeline drug profiles, including Asthma clinical trials and nonclinical stage products. It also covers the Asthma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the Asthma Pipeline treatment landscape of the report, click here @ Asthma Pipeline Outlook
Key Takeaways from the Asthma Pipeline Report
- DelveInsight’s Asthma Pipeline report depicts a robust space with 90+ active players working to develop 100+ pipeline therapies for Asthma.
- The leading Asthma Companies include Jiangsu Hengrui Medicine, GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., ARS Pharmaceuticals, Sanofi, Zura Bio Ltd., AstraZeneca, EURRUS Biotech GmbH, T-Balance Therapeutics GmbH, Gossamer Bio, Aldeyra Therapeutics, Inc., Trio Medicines, Janssen Research & Development, Arrowhead Pharmaceuticals, Hoffman-La-Roche, GlaxoSmithKline, Biohaven Pharmaceutical, TAK-Circulator Co., Shanghai Hengrui Pharmaceutical, and others
- Promising Asthma Pipeline Therapies include A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others.
- The Asthma companies and academics are working to assess challenges and seek opportunities that could influence Asthma R&D. The Asthma therapies under development are focused on novel approaches to treat/improve Asthma.
For further information, refer to the detailed Asthma Unmet Needs, Asthma Market Drivers, and Asthma Market Barriers, click here for Asthma Ongoing Clinical Trial Analysis
Asthma Overview
Asthma is a chronic disease that affects the airways. Asthma is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen. The air passages in the lungs become narrow due to inflammation and tightening of the muscles around the small airways. This causes asthma symptoms: cough, wheeze, shortness of breath, and chest tightness. Asthma is a chronic disease that affects the airways.
Request a sample and discover the recent advances in Asthma Ongoing Clinical Trial Analysis and Medications, click here @ Asthma Treatment Landscape
Asthma Emerging Drugs Profile
- Dexpramipexole: Areteia Therapeutics
Dexpramipexole inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. Most recently in a Phase II study (EXHALE-1) in patients with moderate-to-severe eosinophilic asthma, treatment with dexpramipexole resulted in a significant, dose-dependent reduction in blood absolute eosinophil count at all doses tested (dexpramipexole doses of 37.5 mg, 75 mg, or 150 mg twice daily) compared to placebo. Dexpramipexole was well tolerated in the trial, with adverse events balanced across treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation. Currently the drug is in Phase III stage of clinical trial evaluation for the treatment of Eosinophilic Asthma.
- TQC2731: Chia Tai Tianqing Pharmaceutical Group
TQC2731, belongs to the class of Antiasthmatic. These anti-inflammatory drugs are the most effective and commonly used long-term control medications for asthma. They reduce swelling and tightening in the airways. An Antiasthmatic and antiallergic agent also prevents mast cell release of histamine and formation of other mediators (leukotrienes) of anaphylaxis by inhibiting degranulation after contact with antigens. These helps prevent symptoms of asthma, allergic rhinitis, mastocytosis, and exercise-induced bronchospasm.TQC2731 is currently being investigated in Phase II stage of Clinical trial evaluation for the treatment of Asthma.
- SHR-1703: Jiangsu HengRui Medicine
SHR-1703 injection is a humanized anti- IL-5 monoclonal antibody (IgG1 subtype) that can bind to IL-5 , inhibit the IL-5/IL-5R signaling pathway, and thereby inhibit the proliferation and activation of eosinophils And migration. Reduce the number of asthma attacks in patients with eosinophilic asthma, improve the lung function of patients, and improve the quality of life of patients. The drug is currently in Phase II stage of clinical trial evaluation to treat Asthma.
Dive deep into rich insights for drugs for Asthma Market Drivers and Asthma Market Barriers, click here @ Asthma Unmet Needs and Analyst Views
Asthma Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Asthma. The companies which have their Asthma drug candidates in the most advanced stage, i.e. phase III include, Areteia Therapeutics.
Scope of the Asthma Pipeline Report
- Coverage- Global
- Asthma Companies- Jiangsu Hengrui Medicine, GlaxoSmithKline, Immunotek SL, AB Science, EMS, Avalo Therapeutics, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., ARS Pharmaceuticals, Sanofi, Zura Bio Ltd., AstraZeneca, EURRUS Biotech GmbH, T-Balance Therapeutics GmbH, Gossamer Bio, Aldeyra Therapeutics, Inc., Trio Medicines, Janssen Research & Development, Arrowhead Pharmaceuticals, Hoffman-La-Roche, GlaxoSmithKline, Biohaven Pharmaceutical, TAK-Circulator Co., Shanghai Hengrui Pharmaceutical, and others
- Asthma Pipeline Therapies- A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others.
- Asthma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Asthma Mergers and acquisitions, Asthma Licensing Activities @ Asthma Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Executive Summary
- Asthma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Asthma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Dexpramipexole: Areteia Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- TQC2731: Chia Tai Tianqing Pharmaceutical Group
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- AZD 8630: AstraZeneca
- Drug profiles in the detailed report…..
- Inactive Products
- Asthma Key Companies
- Asthma Key Products
- Asthma – Unmet Needs
- Asthma – Market Drivers and Barriers
- Asthma – Future Perspectives and Conclusion
- Asthma Analyst Views
- Asthma Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
 Co., Ltd., and Others){kind=link}